Zevra Therapeutics combines a deep-value margin of safety and elite quality metrics with a consistent earnings-beat streak, though bearish insider selling and elevated short interest temper the setup.
Thesis pillars
- Deep Value Margin Of Safety—
- Elite Quality Compounder Metrics→Stable
- Earnings Beat Streak Momentum→Stable
- +1 more pillar — see the Why tab for full reasoning
Zevra Therapeutics, Inc. (ZVRA) Stock Analysis
Breakout setup · Inst Constrain edge
Healthcare · Biotechnology
Wait for pullback to $11.10. BUY gates pass at $12.20, but concentration risk — Product: MIPLYFFA (82.0%) argues for a more patient entry. Engine's entry $11.10 (Buy At Market Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum.
Zevra Therapeutics is a commercial-stage rare disease company whose lead product, MIPLYFFA (arimoclomol), was FDA-approved in September 2024 for Niemann-Pick disease type C and generated approximately 82% of the company's 2025 revenue. Zevra also markets OLPRUVA for urea cycle... Read more
Wait for pullback to $11.10. BUY gates pass at $12.20, but concentration risk — Product: MIPLYFFA (82.0%) argues for a more patient entry. Engine's entry $11.10 (Buy At Market Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Chart setup: Golden cross, above all MAs, RSI 67, MACD bullish. Strong overall profile with balanced scores. (held at prior verdict — engine reading is near the momentum/RSI threshold; will commit on clearer signal). Score 7.0/10, high confidence.
Passes 9/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 63d clear, semi cycle peak clear, materials cycle peak clear, sector concentration cap sector=healthcare 6/10 self excluded). Suitability: speculative.
About Zevra Therapeutics, Inc.
About Zevra Therapeutics, Inc.
Zevra Therapeutics derived approximately 82% of its 2025 revenue from MIPLYFFA (arimoclomol), the first FDA-approved treatment for Niemann-Pick disease type C, which reached the U.S. market in November 2024 following a September 2024 FDA approval and had 161 patient enrollments as of December 31, 2025. The company also markets OLPRUVA for urea cycle disorders, though 2025 OLPRUVA revenue was just $0.8 million, and separately earns royalties on AZSTARYS, an ADHD treatment marketed by partner Commave through its affiliate Corium.
Zevra generates revenue primarily from U.S. commercial sales of MIPLYFFA, dispensed through a specialty pharmacy that manages benefits investigations for patients, supplemented by a Global Expanded Access Program that supplies arimoclomol in France, Germany, and other EU markets ahead of a Marketing Authorisation Application now under EMA review. AZSTARYS, an earlier product developed using Zevra's proprietary Ligand Activated Technology platform, is licensed to Commave, whose affiliate Corium handles U.S. commercialization; Zevra collects tiered royalties on net sales plus milestone payments that could reach $590.0 million in the aggregate under the amended license terms, and it received a $148.3 million cash infusion in April 2025 from selling a rare pediatric disease priority review voucher tied to MIPLYFFA's approval. Beyond its commercial products, Zevra is running a Phase 3 trial (DiSCOVER) of celiprolol for Vascular Ehlers-Danlos syndrome, with 52 of a planned 150 patients enrolled as of December 31, 2025, and holds two additional Phase 3-ready candidates built on its serdexmethylphenidate prodrug for idiopathic hypersomnia and narcolepsy.
Show full overview
Zevra's own risk factors go beyond simply naming MIPLYFFA as the revenue leader: they state the company is highly dependent on this one product for substantially all of its revenue, and that because NPC's patient population is so small, even modest shifts in prescribing patterns, patient identification rates, or reimbursement decisions could have a disproportionate effect on results. That concentration is compounded by Zevra's decision to scale back sales and marketing for OLPRUVA while it evaluates strategic alternatives, meaning the company's near-term revenue diversification away from MIPLYFFA is moving in reverse rather than forward even as celiprolol and the KP1077 franchise remain years from potential approval.
See also: Healthcare · Biotechnology
From Zevra Therapeutics, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-09-03Recent Developments — Zevra Therapeutics, Inc.
Latest news
- NEWS ZVRA Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Zevra Therapeutics (ZVRA) - The AI Journa — The AI Journal negative
- NEWS ZVRA Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Zevra Therapeutics (ZVRA) - Business Wire — Business Wire negative
- NEWS ZVRA Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Zevra Therapeutics (ZVRA) - businesswire. — businesswire.com negative
- NEWS ZVRA Stock Plummets Pre-Market, Heads For Worst Day In Over 5 Years – What’s Driving The Sell-Off? - stocktwits.com — stocktwits.com negative
- NEWS Zevra Therapeutics Announces Details for Q2 2026 Financial Results Call - The Manila Times — The Manila Times neutral
Generated 2026-09-03T14:22:19Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductMIPLYFFA82%10-K Item 1A: 'For the year ended December 31, 2025 we derived approximately 82% of our revenues from commercial sales of MIPLYFFA'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $11.10. BUY gates pass at $12.20, but concentration risk — Product: MIPLYFFA (82.0%) argues for a more patient entry. Engine's entry $11.10 (Buy At Market Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Chart setup: Golden cross, above all MAs, RSI 67, MACD bullish. Strong overall profile with balanced scores. (held at prior verdict — engine reading is near the momentum/RSI threshold; will commit on clearer signal). Target $21.75 (+78.3%), stop $10.28 (−18.7%), A.R:R 6.3:1. Score 7.0/10, high confidence.
Take-profit target: $21.75 (+76.8% upside). Target $21.75 (+78.3%), stop $10.28 (−18.7%), A.R:R 6.3:1. Stop-loss: $10.28.
Concentration risk — Product: MIPLYFFA (82.0%).
Zevra Therapeutics, Inc. trades at a P/E of 12.6 (forward 11.5). TrendMatrix value score: 7.5/10. Verdict: Buy (Wait for Entry).
15 analysts cover ZVRA with a consensus score of 4.3/5. Average price target: $25.
What does Zevra Therapeutics, Inc. do?Zevra Therapeutics is a commercial-stage rare disease company whose lead product, MIPLYFFA (arimoclomol), was...
Zevra Therapeutics is a commercial-stage rare disease company whose lead product, MIPLYFFA (arimoclomol), was FDA-approved in September 2024 for Niemann-Pick disease type C and generated approximately 82% of the company's 2025 revenue. Zevra also markets OLPRUVA for urea cycle disorders, though it is scaling back sales and marketing for that product, earns royalties on the partnered ADHD drug AZSTARYS, and is running a Phase 3 trial of celiprolol for Vascular Ehlers-Danlos syndrome.